What are the latest figures on the porcine epidemic diarrhea vaccines market’s size and projected CAGR?
The porcine epidemic diarrhea vaccines market size has grown strongly in recent years. It will grow from $1.67 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to large-scale vaccination campaigns, expanded programs on immunization (EPI), the adoption of disposable syringes, diarrhea eradication efforts, and initiatives like the global alliance for vaccines and immunization (GAVI).
The porcine epidemic diarrhea vaccines market size is expected to see strong growth in the next few years. It will grow to $2.42 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to the growing emphasis on immunization programs, expanded vaccine development pipelines, expanding pig populations, focus on cold chain management, and rising awareness about the importance of preventive healthcare measures. Major trends in the forecast period include continued innovations in vaccine delivery device technology, focus on needle-free solutions, advancements in personalized medicine, growing preference for self-administered vaccines, and strengthening animal healthcare infrastructure and distribution networks.
Get Your Free Sample of The Global Porcine Epidemic Diarrhea Vaccines Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16514&type=smp
Which major factors have contributed to the expansion of the porcine epidemic diarrhea vaccines market?
The increasing pig farming is expected to propel the growth of the porcine epidemic diarrhea vaccine market going forward. Pig farming involves raising domestic pigs for meat production, breeding, rearing, managing from birth to market weight, and marketing and selling pork products. Pig farming is increasing due to rising global demand for pork products, improvements in breeding and management practices, technological advancements in farming techniques, and expanding markets for pork consumption. Porcine epidemic diarrhea (PED) vaccines are employed in pig farming to prevent and manage outbreaks. They are usually administered via injection or orally starting from the sow’s gestation period to confer passive immunity to newborn piglets through colostrum. For instance, according to the United States Department of Agriculture, a US-based government department, in 2022, pork production in the United States reached 40.6 billion pounds, marking a 1 percent increase compared to the previous year. Therefore, the increasing pig farming is driving the growth of the porcine epidemic diarrhea vaccine market.
How is the porcine epidemic diarrhea vaccines market segmented?
The porcine epidemic diarrhea vaccines market covered in this report is segmented –
1) By Product: Live Vaccines, Killed Vaccines
2) By Application: Piglets, Adults Pigs
3) By End-User: Veterinary Hospitals, Hog Production Farms
Subsegments:
1) By Live Vaccines: Oral Live Vaccines, Injectable Live Vaccines
2) By Killed Vaccines: Inactivated Injectable Vaccines, Inactivated Oral Vaccines
Order your report now for swift delivery
Who are the top competitors in the porcine epidemic diarrhea vaccines market?
Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, Elanco Animal Health, Idexx Laboratories Inc., Bio-Rad Laboratories Inc., Ceva Santé Animale Health Company, Phibro Animal Health Corporation, Benchmark Animal Health Ltd., IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Tecnovax, Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Komipharm International Co. Ltd., Boehringer Ingelheim Animal Health, MSD Animal Health, Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc
Which key trends are expected to influence the porcine epidemic diarrhea vaccines market in the coming years?
Major companies operating in the porcine epidemic diarrhea vaccines market are developing innovative products, such as the porcine parvovirus (PPV) vaccine, to strengthen their position in the market. The Porcine Parvovirus (PPV) vaccine is a veterinary immunization designed to prevent reproductive failure in pigs caused by PPV, a small, non-enveloped virus associated with infertility, stillbirths, mummified fetuses, and weak piglets. For instance, in March 2022, Boehringer Ingelheim, a Germany-based pharmaceutical company, launched the ReproCyc ParvoFLEX porcine parvovirus (PPV) vaccine. This innovative vaccine is designed to combat reproductive failure in pigs, including infertility, stillbirths, mummified fetuses, and weak piglets caused by PPV, a small, non-enveloped virus. The uniqueness of this launch lies in the advanced formulation and efficacy of the vaccine, which offers comprehensive protection against PPV-induced reproductive losses, thereby safeguarding the health and productivity of pig herds.
Which regional trends are influencing the porcine epidemic diarrhea vaccines market, and which area dominates the industry?
Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2024. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Porcine Epidemic Diarrhea Vaccines Market Report 2025 Offer?
The porcine epidemic diarrhea vaccines market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Porcine epidemic diarrhea (PED) vaccines are biological preparations developed to provide immunity against the porcine epidemic diarrhea virus (PEDV), which causes severe gastrointestinal disease in pigs. These vaccines are essential tools in preventing and controlling Porcine Epidemic Diarrhea, contributing to the health and productivity of pig populations and the economic stability of the swine industry.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16514
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
